oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2022-21-3-135-142oncotomsk-2171Research ArticleОБЗОРЫREVIEWSБелки ROR1 и BMI-1 как потенциальные факторы прогноза эффективности гормонотерапии при люминальном раке молочной железыROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancerhttps://orcid.org/0000-0001-9472-017XТаракановаВ. О.TarakanovaV. O.

Тараканова Валерия Олеговна, аспирант; ассистент кафедры онкологии

г. Томск, 634009, пер. Кооперативный, 5; г. Томск, 634050, Московский тракт, 2

Valeriia O. Tarakanova, MD, Postgraduate at Department of Cancer Research Institute; Assistant at the Oncology Department

5, Kooperativny St., 634009, Tomsk; 2, Moskovsky Trakt, 634050, Tomsk

valeria.ssmu@gmail.comhttps://orcid.org/0000-0002-1909-1681КрахмальН. В.KrakhmalN. V.

Крахмаль Надежда Валерьевна, кандидат медицинских наук, доцент, старший научный сотрудник отделения общей и молекулярной патологии; доцент кафедры патологической анатомии

г. Томск, 634009, пер. Кооперативный, 5; г. Томск, 634050, Московский тракт, 2

Nadezhda V. Krakhmal, MD, PhD, Associate Professor, Senior Researcher, Department of General and Molecular Pathology; Associate Professor 

5, Kooperativny St., 634009, Tomsk; 2, Moskovsky Trakt, 634050, Tomsk

https://orcid.org/0000-0002-9468-1980ПаталякС. В.PatalyakS. V.

Паталяк Станислав Викторович, кандидат медицинских наук, заведующий онкологическим отделением дневного стационара; ассистент кафедры онкологии

 

г. Томск, 634009, пер. Кооперативный, 5; г. Томск, 634050, Московский тракт, 2

Stanislav V. Patalyak, MD, PhD, Head of the Department of Day hospital, Russian Academy of Sciences; Assistant at the Oncology Department

5, Kooperativny St., 634009, Tomsk; 2, Moskovsky Trakt, 634050, Tomsk

https://orcid.org/0000-0003-3878-2290ТарасовМ Н.TarasovM. N.

Тарасов Михаил Николаевич, ординатор

г. Томск, 634050, Московский тракт, 2

Mikhail N. Tarasov, MD, Resident of Oncology Department

2, Moskovsky Trakt, 634050, Tomsk

https://orcid.org/0000-0002-0562-3878БабышкинаН. Н.BabyshkinaN. N.

Бабышкина Наталия Николаевна, доктор медицинских наук, старший научный сотрудник лаборатории молекулярной онкологии и иммунологии; доцент кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики

г. Томск, 634009, пер. Кооперативный, 5; г. Томск, 634050, Московский тракт, 2

Nataliya N. Babyshkina, MD, DSc, Senior Researcher, Laboratory of Molecular Oncology and Immunology, Russian Academy of Sciences; Associate Professor

5, Kooperativny St., 634009, Tomsk; 2, Moskovsky Trakt, 634050, Tomsk

https://orcid.org/0000-0002-1195-4008ВторушинС. В.VtorushinS. V.

Вторушин Сергей Владимирович, доктор медицинских наук, заведующий отделением общей и молекулярной патологии, Научно-исследовательский институт онкологии; профессор кафедры патологической анатомии

г. Томск, 634009, пер. Кооперативный, 5; г. Томск, 634050, Московский тракт, 2

Sergey V. Vtorushin, MD, DSc, Head of the Department of General and Molecular Pathology; Professor at the Pathology Department

5, Kooperativny St., 634009, Tomsk; 2, Moskovsky Trakt, 634050, Tomsk

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияCancer Research Institute, Тomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияSiberian State Medical University of the Ministry of Health of RussiaRussian Federation202229062022213135142Copyright © Тараканова В.О., Крахмаль Н.В., Паталяк С.В., Тарасов М.Н., Бабышкина Н.Н., Вторушин С.В., 20222022Тараканова В.О., Крахмаль Н.В., Паталяк С.В., Тарасов М.Н., Бабышкина Н.Н., Вторушин С.В.Tarakanova V.O., Krakhmal N.V., Patalyak S.V., Tarasov M.N., Babyshkina N.N., Vtorushin S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/2171

Цель исследования – обобщение имеющихся сведений о возможных молекулярно-биологических механизмах развития неэффективности эндокринотерапии ингибиторами ароматазы у пациентов, больных люминальным раком молочной железы.

Материал и методы

Материал и методы. Поиск литературы производился в системах Medline, Cochrane Library, Elibrary и PubMed, включались публикации, характеризующие современный взгляд на проблему устойчивости опухолей молочной железы к проводимой терапии.

Результаты

Результаты. В обзоре освещены результаты международных исследований молекулярно-биологических характеристик опухолей молочной железы и их связь с эффективностью проводимой гормонотераии. Особое внимание уделено описанию современных исследований по изучению белков ROR1 и BMI-1 и их вклада в развитие устойчивости опухоли к лечению. Проведен анализ мировой литературы, подтверждающий актуальность исследования молекулярных и генетических характеристик опухолевой ткани у пациентов с люминальным РМЖ, сопоставления полученных данных с клиническим течением и ответом на гормонотерапию с целью их стандартизации для внедрения в повседневную практику в качестве «золотого стандарта диагностики».

The purpose of the study was to generalize information regarding the molecular and biological mechanisms involved in the resistance to endocrine therapy with aromatase inhibitors in patients with luminal breast cancer. Material and Methods. The literature search was conducted using Medline, Cochrane Library, Elibrary and PubMed databases. Results. The review highlights the results of international studies on molecular and biological characteristics of breast tumors and their relationship with the effectiveness of hormone therapy. Particular attention was paid to the description of modern studies on ROR1 and BMI-1 proteins and their contribution to the development of tumor resistance to treatment. Conclusion. The analysis of the world literature confrms the relevance of studying the molecular and genetic characteristics of tumor tissue in patients with luminal breast cancer. The data obtained were compared to the clinical course and response to hormone therapy in order to standardize them for implementation in everyday practice as the “gold standard of diagnosis”.

рак молочной железылюминальные подтипыROR1BMI-1адъювантная гормонотерапияbreast cancerluminal subtypesROR1BMI-1adjuvant hormone therapyReferencesSiegel R.L., Jakubowski C.D., Fedewa S.A., Davis A., Azad N.S. Colorectal cancer in the young: epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 2020; 40: 1–14. doi: 10.1200/ EDBK_279901.Siegel R.L., Jakubowski C.D., Fedewa S.A., Davis A., Azad N.S. Colorectal cancer in the young: epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 2020; 40: 1–14. doi: 10.1200/ EDBK_279901.Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19): 10869–74. doi: 10.1073/pnas.191367098.Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19): 10869–74. doi: 10.1073/pnas.191367098.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341–52. doi: 10.1016/S0140-6736(15)61074-1.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341–52. doi: 10.1016/S0140-6736(15)61074-1.Araki K., Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018; 25(4): 392–401. doi: 10.1007/s12282-017-0812-x.Araki K., Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018; 25(4): 392–401. doi: 10.1007/s12282-017-0812-x.Zhao H., Zhou L., Shangguan A.J., Bulun S.E. Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol. 2016; 57(1): 19–33. doi: 10.1530/JME-15-0310.Zhao H., Zhou L., Shangguan A.J., Bulun S.E. Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol. 2016; 57(1): 19–33. doi: 10.1530/JME-15-0310.Gustin J.P., Miller J., Farag M., Rosen D.M., Thomas M., Scharpf R.B., Lauring J. GATA3 frame shift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers. Oncotarget. 2017; 8(61): 103415–427. doi: 10.18632/oncotarget.21910.Gustin J.P., Miller J., Farag M., Rosen D.M., Thomas M., Scharpf R.B., Lauring J. GATA3 frame shift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers. Oncotarget. 2017; 8(61): 103415–427. doi: 10.18632/oncotarget.21910.Emmanuel N., Lofgren K.A., Peterson E.A., Meier D.R., Jung E.H., Kenny P.A. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Res. 2018; 38(8): 4435–41. doi: 10.21873/anticanres.12745.Emmanuel N., Lofgren K.A., Peterson E.A., Meier D.R., Jung E.H., Kenny P.A. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Res. 2018; 38(8): 4435–41. doi: 10.21873/anticanres.12745.Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., Ng S., Lin L., Crowder R., Snider J., Ballman K., Weber J., Chen K., Koboldt D.C., Kandoth C., Schierding W.S., McMichael J.F., Miller C.A., Lu C., Harris C.C., McLellan M.D., Wendl M.C., DeSchryver K., Allred D.C., Esserman L., Unzeitig G., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Leitch M., Hunt K., Olson J., Tao Y., Maher C.A., Fulton L.L., Fulton R.S., Harrison M., Oberkfell B., Du F., Demeter R., Vickery T.L., Elhammali A., Piwnica-Worms H., McDonald S., Watson M., Dooling D.J., Ota D., Chang L.W., Bose R., Ley T.J., Piwnica-Worms D., Stuart J.M., Wilson R.K., Mardis E.R. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486(7403): 353–60. doi: 10.1038/nature11143.Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., Ng S., Lin L., Crowder R., Snider J., Ballman K., Weber J., Chen K., Koboldt D.C., Kandoth C., Schierding W.S., McMichael J.F., Miller C.A., Lu C., Harris C.C., McLellan M.D., Wendl M.C., DeSchryver K., Allred D.C., Esserman L., Unzeitig G., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Leitch M., Hunt K., Olson J., Tao Y., Maher C.A., Fulton L.L., Fulton R.S., Harrison M., Oberkfell B., Du F., Demeter R., Vickery T.L., Elhammali A., Piwnica-Worms H., McDonald S., Watson M., Dooling D.J., Ota D., Chang L.W., Bose R., Ley T.J., Piwnica-Worms D., Stuart J.M., Wilson R.K., Mardis E.R. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486(7403): 353–60. doi: 10.1038/nature11143.Gonzalez R.S., Wang J., Kraus T., Sullivan H., Adams A.L., Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013; 44(6): 1065–70. doi: 10.1016/j.humpath.2012.09.010.Gonzalez R.S., Wang J., Kraus T., Sullivan H., Adams A.L., Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013; 44(6): 1065–70. doi: 10.1016/j.humpath.2012.09.010.Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011; 43(1): 27–33. doi: 10.1038/ng.730.Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011; 43(1): 27–33. doi: 10.1038/ng.730.Ma C.X., Reinert T., Chmielewska I., Ellis M.J. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015; 15(5): 261–75. doi: 10.1038/nrc3920.Ma C.X., Reinert T., Chmielewska I., Ellis M.J. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015; 15(5): 261–75. doi: 10.1038/nrc3920.Generali D., Bates G., Berruti A., Brizzi M.P., Campo L., Bonardi S., Bersiga A., Allevi G., Milani M., Aguggini S., Dogliotti L., Banham A.H., Harris A.L., Bottini A., Fox S.B. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009; 15(3): 1046–51. doi: 10.1158/1078-0432.CCR08-1507.Generali D., Bates G., Berruti A., Brizzi M.P., Campo L., Bonardi S., Bersiga A., Allevi G., Milani M., Aguggini S., Dogliotti L., Banham A.H., Harris A.L., Bottini A., Fox S.B. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009; 15(3): 1046–51. doi: 10.1158/1078-0432.CCR08-1507.De A. Wnt/Ca21 signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai). 2011; 43(10): 745–56. doi: 10.1093/ abbs/gmr079.De A. Wnt/Ca21 signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai). 2011; 43(10): 745–56. doi: 10.1093/ abbs/gmr079.Cai X., Yao Z., Li L., Huang J. Role of DKK4 in Tumorigenesis and Tumor Progression. Int J Biol Sci. 2018; 14(6): 616–21. doi: 10.7150/ ijbs.24329.Cai X., Yao Z., Li L., Huang J. Role of DKK4 in Tumorigenesis and Tumor Progression. Int J Biol Sci. 2018; 14(6): 616–21. doi: 10.7150/ ijbs.24329.Hasan K., Widhopf 2nd G.F., Zhang S., Lam S.M., Shen Z., Briggs S.P., Parker B.A., Kipps T.J. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5: 35. doi: 10.1038/s41523-019-0131-9.Hasan K., Widhopf 2nd G.F., Zhang S., Lam S.M., Shen Z., Briggs S.P., Parker B.A., Kipps T.J. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5: 35. doi: 10.1038/s41523-019-0131-9.Zhang S., Zhang H., Ghia E.M., Huang J., Wu L., Zhang J., Lam S., Lei Y., He J., Cui B., Widhopf 2nd G.F., Yu J., Schwab R., Messer K., Jiang W., Parker B.A., Carson D.A., Kipps T.J. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specifc antibody. Proc Natl Acad Sci USA. 2019; 116(4): 1370–7. doi: 10.1073/pnas.1816262116.Zhang S., Zhang H., Ghia E.M., Huang J., Wu L., Zhang J., Lam S., Lei Y., He J., Cui B., Widhopf 2nd G.F., Yu J., Schwab R., Messer K., Jiang W., Parker B.A., Carson D.A., Kipps T.J. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specifc antibody. Proc Natl Acad Sci USA. 2019; 116(4): 1370–7. doi: 10.1073/pnas.1816262116.Karvonen H., Barker H., Kaleva L., Niininen W., Ungureanu D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019; 8(8): 812. doi: 10.3390/cells8080812.Karvonen H., Barker H., Kaleva L., Niininen W., Ungureanu D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019; 8(8): 812. doi: 10.3390/cells8080812.Borcherding N., Kusner D., Liu G.H., Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 2014; 5(7): 496–502. doi: 10.1007/s13238-014-0059-7.Borcherding N., Kusner D., Liu G.H., Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 2014; 5(7): 496–502. doi: 10.1007/s13238-014-0059-7.Balakrishnan A., Goodpaster T., Randolph-Habecker J., Hoffstrom B.G., Jalikis F.G., Koch L.K., Berger C., Kosasih P.L., Rajan A., Sommermeyer D., Porter P.L., Riddell S.R. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res. 2017; 23(12): 3061–71. doi: 10.1158/1078-0432.CCR-16-2083.Balakrishnan A., Goodpaster T., Randolph-Habecker J., Hoffstrom B.G., Jalikis F.G., Koch L.K., Berger C., Kosasih P.L., Rajan A., Sommermeyer D., Porter P.L., Riddell S.R. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res. 2017; 23(12): 3061–71. doi: 10.1158/1078-0432.CCR-16-2083.Zhang S., Zhao X., Zhang D. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol. 2014; 11(3): 314. doi: 10.1038/cmi.2014.18.Zhang S., Zhao X., Zhang D. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol. 2014; 11(3): 314. doi: 10.1038/cmi.2014.18.Saleh R.R., Antrás J.F., Peinado P., Pérez-Segura P., Pandiella A., Amir E., Ocaña A. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. Cancer Treat Rev. 2019; 77: 11–9. doi: 10.1016/j.ctrv.2019.05.006.Saleh R.R., Antrás J.F., Peinado P., Pérez-Segura P., Pandiella A., Amir E., Ocaña A. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. Cancer Treat Rev. 2019; 77: 11–9. doi: 10.1016/j.ctrv.2019.05.006.Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., Lanchbury J.S., Stemke-Hale K., Hennessy B.T., Arun B.K., Hortobagyi G.N., Do K.A., Mills G.B., Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptornegative breast cancer. Clin Cancer Res. 2011; 17(5): 1082–9. doi: 10.1158/1078-0432.CCR-10-2560.Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., Lanchbury J.S., Stemke-Hale K., Hennessy B.T., Arun B.K., Hortobagyi G.N., Do K.A., Mills G.B., Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptornegative breast cancer. Clin Cancer Res. 2011; 17(5): 1082–9. doi: 10.1158/1078-0432.CCR-10-2560.Li C., Wang S., Xing Z., Lin A., Liang K., Song J., Hu Q., Yao J., Chen Z., Park P.K., Hawke D.H., Zhou J., Zhou Y., Zhang S., Liang H., Hung M.C., Gallick G.E., Han L., Lin C., Yang L. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017; 19(2): 106–19. doi: 10.1038/ncb3464.Li C., Wang S., Xing Z., Lin A., Liang K., Song J., Hu Q., Yao J., Chen Z., Park P.K., Hawke D.H., Zhou J., Zhou Y., Zhang S., Liang H., Hung M.C., Gallick G.E., Han L., Lin C., Yang L. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017; 19(2): 106–19. doi: 10.1038/ncb3464.Cao J., Wang X., Dai T., Wu Y., Zhang M., Cao R., Zhang R., Wang G., Jiang R., Zhou B.P., Shi J., Kang T. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. Theranostics. 2018; 8(10): 2739–51. doi: 10.7150/thno.21477.Cao J., Wang X., Dai T., Wu Y., Zhang M., Cao R., Zhang R., Wang G., Jiang R., Zhou B.P., Shi J., Kang T. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. Theranostics. 2018; 8(10): 2739–51. doi: 10.7150/thno.21477.Hammer A., Laghate S., Diakonova M. Src tyrosyl phosphorylates cortactin in response to prolactin. Biochem Biophys. Res. Commun. 2015; 463: 644–9. doi: 10.1016/j.bbrc.2015.05.116.Hammer A., Laghate S., Diakonova M. Src tyrosyl phosphorylates cortactin in response to prolactin. Biochem Biophys. Res. Commun. 2015; 463: 644–9. doi: 10.1016/j.bbrc.2015.05.116.Pandey G., Borcherding N., Kolb R., Kluz P., Li W., Sugg S., Zhang J., Lai D.A., Zhang W. ROR1 Potentiates FGFR Signaling in BasalLike Breast Cancer. Cancers (Basel). 2019; 11(5): 718. doi: 10.3390/ cancers11050718.Pandey G., Borcherding N., Kolb R., Kluz P., Li W., Sugg S., Zhang J., Lai D.A., Zhang W. ROR1 Potentiates FGFR Signaling in BasalLike Breast Cancer. Cancers (Basel). 2019; 11(5): 718. doi: 10.3390/ cancers11050718.Fultang N., Illendula A., Lin J., Pandey M.K., Klase Z., Peethambaran B. ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efux pump ABCB1. Sci Rep. 2020; 10(1): 1821. doi: 10.1038/ s41598-020-58864-0.Fultang N., Illendula A., Lin J., Pandey M.K., Klase Z., Peethambaran B. ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efux pump ABCB1. Sci Rep. 2020; 10(1): 1821. doi: 10.1038/ s41598-020-58864-0.Yu J., Chen L., Cui B., Widhopf G.F. 2nd, Shen Z., Wu R., Zhang L., Zhang S., Briggs S.P., Kipps T.J. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016; 126(2): 585-98. doi: 10.1172/JCI83535.Yu J., Chen L., Cui B., Widhopf G.F. 2nd, Shen Z., Wu R., Zhang L., Zhang S., Briggs S.P., Kipps T.J. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016; 126(2): 585-98. doi: 10.1172/JCI83535.Faião-Flores F., Emmons M.F., Durante M.A., Kinose F., Saha B., Fang B., Koomen J.M., Chellappan S.P., Maria-Engler S.S., Rix U., Licht J.D., Harbour J.W., Smalley K.S.M. HDAC Inhibition Enhances the In Vivo Efcacy of MEK Inhibitor Therapy in Uveal Melanoma. Clin Cancer Res. 2019; 25(18): 5686–5701. doi: 10.1158/1078-0432.CCR-18-3382.Faião-Flores F., Emmons M.F., Durante M.A., Kinose F., Saha B., Fang B., Koomen J.M., Chellappan S.P., Maria-Engler S.S., Rix U., Licht J.D., Harbour J.W., Smalley K.S.M. HDAC Inhibition Enhances the In Vivo Efcacy of MEK Inhibitor Therapy in Uveal Melanoma. Clin Cancer Res. 2019; 25(18): 5686–5701. doi: 10.1158/1078-0432.CCR-18-3382.Hoefich K.P., Guan J., Edgar K.A., O’Brien C., Savage H., Wilson T.R., Neve R.M., Friedman L.S., Wallin J.J. The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes Cancer. 2016; 7(3–4): 73–85. doi: 10.18632/ genesandcancer.100.Hoefich K.P., Guan J., Edgar K.A., O’Brien C., Savage H., Wilson T.R., Neve R.M., Friedman L.S., Wallin J.J. The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes Cancer. 2016; 7(3–4): 73–85. doi: 10.18632/ genesandcancer.100.Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366(6): 520–9. doi: 10.1056/NEJMoa1109653.Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366(6): 520–9. doi: 10.1056/NEJMoa1109653.Gray F., Cho H.J., Shukla S., He S., Harris A., Boytsov B., Jaremko Ł., Jaremko M., Demeler B., Lawlor E.R., Grembecka J., Cierpicki T. BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization. Nat Commun. 2016; 7: 13343. doi: 10.1038/ ncomms13343.Gray F., Cho H.J., Shukla S., He S., Harris A., Boytsov B., Jaremko Ł., Jaremko M., Demeler B., Lawlor E.R., Grembecka J., Cierpicki T. BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization. Nat Commun. 2016; 7: 13343. doi: 10.1038/ ncomms13343.Claude-Taupin A., Boyer-Guittaut M., Delage-Mourroux R., Hervouet E. Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies. Methods Mol Biol. 2015; 1238: 487–509. doi: 10.1007/978-1-4939-1804-1_25.Claude-Taupin A., Boyer-Guittaut M., Delage-Mourroux R., Hervouet E. Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies. Methods Mol Biol. 2015; 1238: 487–509. doi: 10.1007/978-1-4939-1804-1_25.Kreso A., van Galen P., Pedley N.M., Lima-Fernandes E., Frelin C., Davis T., Cao L., Baiazitov R., Du W., Sydorenko N., Moon Y.C., Gibson L., Wang Y., Leung C., Iscove N.N., Arrowsmith C.H., Szentgyorgyi E., Gallinger S., Dick J.E., O’Brien C.A. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014; 20(1): 29–36. doi: 10.1038/ nm.3418.Kreso A., van Galen P., Pedley N.M., Lima-Fernandes E., Frelin C., Davis T., Cao L., Baiazitov R., Du W., Sydorenko N., Moon Y.C., Gibson L., Wang Y., Leung C., Iscove N.N., Arrowsmith C.H., Szentgyorgyi E., Gallinger S., Dick J.E., O’Brien C.A. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014; 20(1): 29–36. doi: 10.1038/ nm.3418.Bolomsky A., Schlangen K., Schreiner W., Zojer N., Ludwig H. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol. 2016; 9: 17. doi: 10.1186/s13045-016-0247-4.Bolomsky A., Schlangen K., Schreiner W., Zojer N., Ludwig H. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol. 2016; 9: 17. doi: 10.1186/s13045-016-0247-4.Darwish N.H., Sudha T., Godugu K., Elbaz O., Abdelghaffar H.A., Hassan E.E., Mousa S.A. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016; 7(36): 57811–20. doi: 10.18632/ oncotarget.11063.Darwish N.H., Sudha T., Godugu K., Elbaz O., Abdelghaffar H.A., Hassan E.E., Mousa S.A. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016; 7(36): 57811–20. doi: 10.18632/ oncotarget.11063.Sahasrabuddhe A.A. BMI1: A Biomarker of Hematologic Malignancies. Biomark Cancer. 2016; 8: 65–75. doi: 10.4137/BIC.S33376.Sahasrabuddhe A.A. BMI1: A Biomarker of Hematologic Malignancies. Biomark Cancer. 2016; 8: 65–75. doi: 10.4137/BIC.S33376.Althobiti M., Muftah A.A., Aleskandarany M.A., Joseph C., Toss M.S., Green A., Rakha E. The prognostic signifcance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. Breast Cancer Res Treat. 2020; 182(3): 581–9. doi: 10.1007/s10549-020- 05719-x.Althobiti M., Muftah A.A., Aleskandarany M.A., Joseph C., Toss M.S., Green A., Rakha E. The prognostic signifcance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. Breast Cancer Res Treat. 2020; 182(3): 581–9. doi: 10.1007/s10549-020- 05719-x.

The authors declare that there are no conflicts of interest present.